Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes
Authors:
- Warwick J. AdamsWAWarwick J. Adams
Open Access
Abstract
BACKGROUND Previous studies have suggested that cimetidine, a histamine‐2 receptor antagonist with immunostimulatory effects, may improve survival in patients with colorectal carcinoma. This effect may be apparent by an increase in the number of peritumoral lymphocytes. A prospective, double blind, randomized, placebo‐controlled trial of a short course of preoperative treatment with cimetidine in patients with colorectal carcinoma was performed to assess the effect of cimetidine on survival and on the number of peritumoral lymphocytes. METHODS One hundred and twenty‐five patients who were scheduled to undergo elective colon or rectal excision for carcinoma were randomized to receive either placebo or cimetidine preoperatively for 5 days. In addition to standard histopathology, immunohistochemistry and computer video image analysis were used to assess the number of peritumoral lymphocytes in an objective manner. Interim survival analysis according to the Kaplan‐Meier method was performed. RESULTS A trend toward a survival advantage in the group of patients receiving cimetidine (800 mg twice daily) compared with the placebo group was observed (P = 0.20, log rank test) that was most marked in patients with replication error negative tumors (P = 0.04). Similarly, in these two groups there was a trend toward an increase in the number of patients with a conspicuous lymphocytic infiltration (P = 0.10, chi‐square test). However, there was no difference in the number of peritumoral lymphocytes as measured by image analysis. CONCLUSIONS Based on the results of the current study, a short course of preoperative treatment with cimetidine does appear to have an effect on patient survival; however, the exact mechanism is unknown. The failure of this study to demonstrate a clear increase in the local lymphocyte response does not exclude an immunologic mechanism of action. Cancer 1999;85:1658–63. © 1999 American Cancer Society.Keywords
This publication has 13 references indexed in Scilit:
- Pilot study?cimetidine enhances lymphocyte infiltration of human colorectal carcinomaCancer, 1997
- Cimetidine and survival with colorectal cancerThe Lancet, 1995
- Cimetidine as an adjuvant treatment in colorectal cancerDiseases of the Colon & Rectum, 1995
- Impact of the Crohn's-like lymphoid reaction on staging of right-sided colon cancer: Results of multivariate analysisHuman Pathology, 1995
- Short-course cimetidine and survival with colorectal cancerThe Lancet, 1994
- CIMETIDINE PRESERVES NON‐SPECIFIC IMMUNE FUNCTION AFTER COLONIC RESECTION FOR CANCERAnz Journal of Surgery, 1994
- Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth.Gut, 1994
- In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patientsInternational Journal of Immunopharmacology, 1992
- The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 casesHistopathology, 1986
- Colonic carcinoma.A quantitative assessment of lymphocyte infiltration at the periphery of colonic tumors related to prognosisCancer, 1978